V900425
3,4-Dihydroxy-L-phenylalanine
Vetec™, reagent grade, 98%
Synonym(s):
3-(3,4-Dihydroxyphenyl)-L-alanine, L-3-Hydroxytyrosine, L-DOPA, Levodopa
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
(HO)2C6H3CH2CH(NH2)CO2H
CAS Number:
Molecular Weight:
197.19
EC Number:
200-445-2
UNSPSC Code:
12352209
PubChem Substance ID:
Beilstein/REAXYS Number:
2215169
MDL number:
grade
reagent grade
product line
Vetec™
assay
98%
mp
276-278 °C (lit.)
SMILES string
N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O
InChI
1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
InChI key
WTDRDQBEARUVNC-LURJTMIESA-N
Gene Information
human ... DRD3(1814)
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under 3,4-Dihydroxy-L-phenylalanine
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Molly J Crockett et al.
Current biology : CB, 25(14), 1852-1859 (2015-07-07)
An aversion to harming others is a core component of human morality and is disturbed in antisocial behavior. Deficient harm aversion may underlie instrumental and reactive aggression, which both feature in psychopathy. Past work has highlighted monoaminergic influences on aggression
Ezekiel J Maier et al.
Genome research, 25(5), 690-700 (2015-02-04)
Key steps in understanding a biological process include identifying genes that are involved and determining how they are regulated. We developed a novel method for identifying transcription factors (TFs) involved in a specific process and used it to map regulation
Roshan Cools
Neuroscience and biobehavioral reviews, 30(1), 1-23 (2005-06-07)
It is well recognised that patients with Parkinson's disease exhibit cognitive deficits, even in the earliest disease stages. Whereas, L-DOPA therapy in early Parkinson's disease is accepted to improve the motor symptoms, the effects on cognitive performance are more complex:
Global Trade Item Number
| SKU | GTIN |
|---|---|
| V900425-100G | 04061833008324 |